Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

被引：1
|
作者：
Mehta, Pallavi [1 ]
Yadav, Neha [1 ]
Bhaarat, Mohan [2 ]
Mirgh, Sumeet Prakash [3 ]
Khushoo, Vishvdeep [3 ]
Thekuddan, Shinto Francis [1 ]
Agrawal, Narendra [3 ]
Ahmed, Rayaz [4 ]
Bhurani, Dinesh [3 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol, New Delhi, India
[2] Rajiv Gandhi Canc Inst, New Delhi, India
[3] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol & BMT, New Delhi, India
[4] Rajiv Gandhi Canc Inst & Res Inst, New Delhi, India
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131674
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5572
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
    Pierceall, William E.
    Amatangelo, Michael D.
    Bahlis, Nizar J.
    Siegel, David S.
    Rahman, Adeeb
    Van Oekelen, Oliver
    Neri, Paola
    Young, Mary
    Chung, Weiyuan
    Serbina, Natalya
    Parekh, Samir
    Agarwal, Amit
    Thakurta, Anjan
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5895 - 5902
  • [42] Retrospective Analysis of a Weekly Carfilzomib-Dexamethasone Regimen in Relapsed/Refractory Multiple Myeloma: Single Center Experience
    Menguc, Meral Ulukoylu
    Gunhan, Hatice Gizem
    Sisman, Ibrahim Talha
    Salim, Secil
    Atagunduz, Isik
    Yilmaz, Asu Fergun
    Toptas, Tayfur
    Arikan, Fatma
    Yanik, Ahmet Mert
    Demirtas, Derya
    Candan, Ozlem
    Tuglular, Ayse Tulin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S539 - S539
  • [43] FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY
    Jakubowiak, A. J.
    Rosenbaum, C. A.
    Stephens, L.
    Kukreti, V.
    Cole, C.
    Zimmerman, T.
    Reece, D.
    Berdeja, J.
    Severson, E.
    Wolfe, B.
    Major, S.
    McDonnell, K.
    Nam, J.
    Turowski, A.
    Griffith, K.
    Zonder, J.
    HAEMATOLOGICA, 2017, 102 : 271 - 271
  • [44] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [45] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
    De Miguel, D.
    Gil, A.
    Golbano, N.
    Diaz, M.
    Guillen, H.
    Vazquez, A.
    Pinedo, B.
    HAEMATOLOGICA, 2017, 102 : 790 - 791
  • [46] Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
    Onda, Yoshiyuki
    Kanda, Junya
    Kaneko, Hitomi
    Shimura, Yuji
    Fuchida, Shin-ichi
    Nakaya, Aya
    Itou, Tomoki
    Yamamura, Ryosuke
    Tanaka, Hirokazu
    Shibayama, Hirohiko
    Shimazu, Yutaka
    Uchiyama, Hitoji
    Yoshihara, Satoshi
    Adachi, Yoko
    Matsuda, Mitsuhiro
    Hanamoto, Hitoshi
    Uoshima, Nobuhiko
    Kosugi, Satoru
    Ohta, Kensuke
    Yagi, Hideo
    Kanakura, Yuzuru
    Matsumura, Itaru
    Hino, Masayuki
    Nomura, Shosaku
    Shimazaki, Chihiro
    Takaori-Kondo, Akifumi
    Kuroda, Junya
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [47] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [48] Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study
    Jasielec, Jagoda
    Zonder, Jeff
    Derman, Benjamin A.
    Reece, Donna E.
    Cole, Craig E.
    Berdeja, Jesus G.
    Wolfe, Brittany
    Major, Sarah
    Tinari, Kathryn M.
    Stefka, Andrew
    Fazzi, Fabrizio
    Whelan, Megan
    Gleason, Christine
    McIver, Amanda
    Andreatos, Evangelia
    Libao, Bernadette M.
    Juergens, Daniel
    Griffith, Kent
    Jakubowiak, Andrzej
    BLOOD, 2020, 136
  • [49] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    Blood Cancer Journal, 9
  • [50] Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    De Novellis, Danilo
    Derudas, Daniele
    Vincelli, Donatella
    Fontana, Raffaele
    Della Pepa, Roberta
    Palmieri, Salvatore
    Accardi, Fabrizio
    Rotondo, Francesco
    Morelli, Emanuela
    Gigliotta, Emilia
    Roccotelli, Daniela
    Marano, Luana
    Barone, Maria Lucia
    Cetani, Giusy
    Esposito, Daniela
    Lazzaro, Antonio
    Delle Cave, Giuseppe
    Serio, Bianca
    Morini, Denise
    Porrazzo, Marika
    Urciuoli, Eleonora
    Masucci, Chiara
    Fanelli, Fulvia
    Rizzo, Michela
    Arcamone, Manuela
    Trastulli, Fabio
    Rocco, Stefano
    Leone, Aldo
    Bianco, Rosario
    Salvatore, Flavia
    Idato, Aurora
    Sicari, Maria
    Tosi, Patrizia
    Rascato, Maria Gabriella
    Di Perna, Maria
    Falcone, Antonietta Pia
    Morello, Lucia
    Carlisi, Melania
    Svanera, Gino
    Annunziata, Mario
    Frigeri, Ferdinando
    Califano, Catello
    Carella, Angelo Michele
    Marcacci, Gianpaolo
    Pane, Fabrizio
    Risitano, Antonio Maria
    Giudice, Valentina
    Botta, Ciro
    Selleri, Carmine
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (01) : 105 - 114
12345